Molnupiravir

• UNSPSC Description:

  Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].

• Target Antigen:

  Influenza Virus; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/eidd-2801.html

• Smiles:

  O=C(N([C@@]1([H])[C@H](O)[C@H](O)[C@@]([H])(COC(C(C)C)=O)O1)C=C2)NC2=NO

• Molecular Weight:

  329.31

• References & Citations:

  [1]Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866.|[2]Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883.

• Shipping Conditions:

  Room Temperature

• CAS Number:

  2492423-29-5